Literature DB >> 8829251

The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS).

P R McElhatton1, H M Garbis, E Eléfant, T Vial, B Bellemin, P Mastroiacovo, J Arnon, E Rodríguez-Pinilla, C Schaefer, T Pexieder, P Merlob, S Dal Verme.   

Abstract

The European Network of the Teratology Information Services (ENTIS) has collected and evaluated data on 689 pregnancies in which exposure to tricyclic and nontricyclic antidepressants occurred. Data were collected prospectively from the time of in utero exposure and all the cases were followed up to the first few weeks of postnatal life using standardized procedures. In most cases, no longer term follow-up data were available. Approximately two-thirds of the mothers were on multidrug therapy, and of those, half took a benzodiazepine. About 95% of the patients were exposed during the first trimester. The most striking feature of the pregnancy outcomes is that 97% of live-born babies were morphologically normal. The incidence of spontaneous abortion and late fetal/neonatal deaths were within the normal range. Fourteen live-born babies and one fetus had either major or minor malformations, and six had minor anomalies. However, there was no increase in either a particular type of malformation or a specific pattern of defects. Another 31 infants without malformations had neonatal problems; these were usually associated with chronic multidrug therapy, especially near term. Elective termination of pregnancy occurred more frequently in the multidrug groups (86 out of 488) than in the monotherapy groups (20 out of 201), but data concerning the condition of the fetus are not available in the majority of the cases. Overall, no causal relationship could be established between in utero exposure to antidepressants and adverse pregnancy outcome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8829251     DOI: 10.1016/0890-6238(96)00057-3

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  30 in total

Review 1.  Drug-induced congenital defects: strategies to reduce the incidence.

Authors:  M De Santis; B Carducci; A F Cavaliere; L De Santis; G Straface; A Caruso
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Antidepressants and breast-feeding: a review of the literature.

Authors:  S Dodd; A Buist; T R Norman
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 3.  Monoamine oxidases in development.

Authors:  Chi Chiu Wang; Ellen Billett; Astrid Borchert; Hartmut Kuhn; Christoph Ufer
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

4.  The use of central nervous system active drugs during pregnancy.

Authors:  Bengt Källén; Natalia Borg; Margareta Reis
Journal:  Pharmaceuticals (Basel)       Date:  2013-10-10

5.  Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records.

Authors:  Bengt Källén; Emma Nilsson; Petra Otterblad Olausson
Journal:  Eur J Clin Pharmacol       Date:  2011-03-09       Impact factor: 2.953

Review 6.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

Review 7.  [Analgesic drugs during pregnancy].

Authors:  S Hultzsch; C Schaefer
Journal:  Schmerz       Date:  2016-12       Impact factor: 1.107

Review 8.  Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies.

Authors:  Shan-Yan Gao; Qi-Jun Wu; Tie-Ning Zhang; Zi-Qi Shen; Cai-Xia Liu; Xin Xu; Chao Ji; Yu-Hong Zhao
Journal:  Br J Clin Pharmacol       Date:  2017-06-10       Impact factor: 4.335

9.  Safety of treatment of obsessive compulsive disorder in pregnancy and puerperium.

Authors:  Shirin Namouz-Haddad; Irena Nulman
Journal:  Can Fam Physician       Date:  2014-02       Impact factor: 3.275

Review 10.  [Psychopharmacotherapy during pregnancy : Which antipsychotics, tranquilizers and hypnotics are suitable?].

Authors:  N Bergemann; W E Paulus
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.